Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.
Duetz C, Westers TM, In 't Hout FEM, Cremers EMP, Alhan C, Venniker-Punt B, Visser-Wisselaar HA, Chitu DA, de Graaf AO, Smit L, Jansen JH, van de Loosdrecht AA. Duetz C, et al. Among authors: in t hout fem. Br J Haematol. 2021 May;193(4):798-803. doi: 10.1111/bjh.17414. Epub 2021 Mar 25. Br J Haematol. 2021. PMID: 33765355 Free PMC article. Clinical Trial.
TCF4 promotes erythroid development.
In 't Hout FEM, van Duren J, Monteferrario D, Brinkhuis E, Mariani N, Westers TM, Chitu D, Nikoloski G, van de Loosdrecht AA, van der Reijden BA, Jansen JH, Huls G. In 't Hout FEM, et al. Exp Hematol. 2019 Jan;69:17-21.e1. doi: 10.1016/j.exphem.2018.10.002. Epub 2018 Oct 10. Exp Hematol. 2019. PMID: 30315825 Free article.
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.
van de Loosdrecht AA, Cremers EMP, Alhan C, Duetz C, In 't Hout FEM, Visser-Wisselaar HA, Chitu DA, Verbrugge A, Cunha SM, Ossenkoppele GJ, Janssen JJWM, Klein SK, Vellenga E, Huls GA, Muus P, Langemeijer SMC, de Greef GE, Te Boekhorst PAW, Raaijmakers MHG, van Marwijk Kooy M, Legdeur MC, Wegman JJ, Deenik W, de Weerdt O, van Maanen-Lamme TM, Jobse P, van Kampen RJW, Beeker A, Wijermans PW, Biemond BJ, Tanis BC, van Esser JWJ, Schaar CG, Noordzij-Nooteboom HS, Jacobs EMG, de Graaf AO, Jongen-Lavrencic M, Stevens-Kroef MJPL, Westers TM, Jansen JH. van de Loosdrecht AA, et al. Among authors: in t hout fem. Leukemia. 2024 Apr;38(4):840-850. doi: 10.1038/s41375-024-02161-6. Epub 2024 Jan 31. Leukemia. 2024. PMID: 38297135 Free PMC article. Clinical Trial.
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J, In 't Hout FE, Devillier R, van Putten WL, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJ, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ. Versluis J, et al. Leukemia. 2017 Jan;31(1):26-33. doi: 10.1038/leu.2016.183. Epub 2016 Jun 24. Leukemia. 2017. PMID: 27416910 Free article.
[Medicinal cannabis].
van den Elsen GAH, In 't Hout FEM, de Vries M, Olde Rikkert MGM, Kramers C, Verkes RJ. van den Elsen GAH, et al. Among authors: in t hout fem. Ned Tijdschr Geneeskd. 2019 May 3;163:D3629. Ned Tijdschr Geneeskd. 2019. PMID: 31120212 Review. Dutch.